Page last updated: 2024-10-28

ibudilast and Parkinson Disease

ibudilast has been researched along with Parkinson Disease in 1 studies

Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)

Research Excerpts

ExcerptRelevanceReference

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Schwenkgrub, J1
Zaremba, M1
Joniec-Maciejak, I1
Cudna, A1
Mirowska-Guzel, D1
Kurkowska-Jastrzębska, I1

Other Studies

1 other study available for ibudilast and Parkinson Disease

ArticleYear
The phosphodiesterase inhibitor, ibudilast, attenuates neuroinflammation in the MPTP model of Parkinson's disease.
    PloS one, 2017, Volume: 12, Issue:7

    Topics: Animals; Astrocytes; Disease Models, Animal; Glial Cell Line-Derived Neurotrophic Factor; Interleuki

2017